NCT03127189View on ClinicalTrials.gov

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

April 10, 2018

Study Completion Date

April 10, 2018

Conditions

Healthy

Interventions

DRUG

Rilpivirine

Rilpivirine 25 mg immediate release oral solution.

DRUG

Rilpivirine Long-acting Parenteral Formulation

RPV LA 600 mg extended-release suspension for IM injection.

Trial Locations (2)

68502

Celerion, Lincoln

85283

Celerion, Tempe

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03127189 - A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants | Biotech Hunter | Biotech Hunter